Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Taipei Medical Univ. DOT1L compound 12
- Development stage
- Unknown
- Lead developer
- Taipei Medical University
01
Overview
Taipei Medical Univ. DOT1L compound 12: sourced facts only. name: "Moreover, compound 12 possessed relatively potent DOT1L inhibitory activity by significantly reduced histone H3 di-methylation at lysine 79 (H3K79me2) level in cells." [PMID:39299178]; target: "Moreover, compound 12 possessed relatively potent DOT1L inhibitory activity by significantly reduced histone H3 di-methylation at lysine 79 (H3K79me2) level in cells." [PMID:39299178]; developer: "School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan." [PMID:39299178]
02
Targets
DOT1L
Beyond the preview
Go deeper on Taipei Medical Univ. DOT1L compound 12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taipei Medical Univ. DOT1L compound 12.